90940-59-3

Usage

InChI:InChI=1/C20H26N2O6/c1-3-28-20(27)15(10-9-14-7-5-4-6-8-14)21-13(2)18(24)22-16(19(25)26)11-12-17(22)23/h4-8,13,15-16,21H,3,9-12H2,1-2H3,(H,25,26)/t13-,15?,16-/m0/s1

Upstream product

• 98049-19-5 -(S)-alanyl>-(S)-pyroglutamic acid tert-butyl ester 
• 90891-25-1 -(S)-alanyl>-(S)-pyroglutamic acid benzyl ester 
• 943-73-7 D-homophenylalanine 
• 94885-52-6 benzyl (L)-pyroglutamate 
• 97998-68-0 N-<1(S)-(ethoxycarbonyl)-3-phenylpropyl>-(RS)-alanine N-oxysuccinimidyl ester 
• 90891-21-7 L-(+)-α-amino-4-phenylbutyric acid ethyl ester hydrochloride 
• 90988-18-4 N-<1(S)-(ethoxycarbonyl)-3-phenylpropyl>-(RS)-alanine 
• 98-79-3 L-Pyroglutamic acid 
• 35418-16-7 L-t-butyl pyroglutamate 
• 82717-96-2 [1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanine 

Relevant academic research and scientific papers

Synthesis and Pharmacology of the Potent Angiotensin-Converting Enzyme Inhibitor N--(S)-alanyl-(S)-pyroglutamic Acid

Structure 3a, a potent angiotensin-converting enzyme inhibitor, was prepared in five steps from L-(+)-α-amino-4-phenylbutyric acid by construction of the activated side-chain ester 16, displacement with L-pyroglutamate ester anion, and deblocking.Diastereomer separation was accomplished by chromatography at the diester stage, 17.Pharmacological assays established that 3a parallels enalapril in its ability to inhibit converting enzyme and lower blood pressure.